Based on data from the EU-SILC survey, unmet need for medical care due to cost, distance and other reasons in Denmark is relatively low, with only 1.3% of the population reporting such unmet needs compared to the EU average of 3.2% (Figure 13). Coverage decisions for new pharmaceuticals are relatively quick, taking between one and two months in Denmark. Residents have the right to seek treatment anywhere in the country if their home region does not provide a service delivered elsewhere (in these cases, the home region needs to cover the expenses of treatment). This includes a project to collect and store genetic information from 100 000 people and a funding pool to enable precision medicine research. Patients with high annual outpatient medicine expenses (over DKK 3 04S or EUR 400) and those with low personal assets (below DKK 77 S00 or EUR 10 400) receive 85% reimbursement for all drugs (Commonwealth Fund, 2015).